STOCKHLOM, June 1, 2021
/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today
announces that the company will present at the virtual meeting
Redeye Growth Day on June 2,
2021.
The presentation is live broadcasted and can be followed at:
https://www.redeye.se/events/808637/redeye-growth-day-2021
The presentation will be available after the meeting on
Medivirs website; www.medivir.com.For additional
information, please contact
Magnus Christensen, interim CEO
and CFOTelephone: +46 8 5468 3100E-mail:
magnus.christensen@medivir.com
Medivir in brief
Medivir develops innovative drugs with a focus on cancer where
the unmet medical needs are high. The drug candidates are directed
toward indication areas where available therapies are limited or
missing and there are great opportunities to offer significant
improvements to patients. Medivir is focusing on the development of
MIV-818, a pro-drug designed to selectively treat liver cancer
cells and to minimize side effects.
Collaborations and partnerships are important parts of Medivir's
business model, and the drug development is conducted either by
Medivir or in partnership. Birinapant, a SMAC mimetic, is
exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be
developed in combination with IGM-antibodies for the treatment of
solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq
Stockholm's Small Cap list. www.medivir.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/medivir/r/medivir-to-present-at-the-redeye-growth-day,c3358116
The following files are available for download:
|
https://mb.cision.com/Main/652/3358116/1425725.pdf
|
Press release
(PDF)
|
View original
content:http://www.prnewswire.com/news-releases/medivir-to-present-at-the-redeye-growth-day-301302618.html
SOURCE Medivir
